people장 홈📈 Stock Masters주식 유튜브를 Articles로 읽고 Author의 예측을 실제 가격으로 확인합니다 people장 Board 홈요청하기

한국어 · English

제레미그랜섬

Accuracy score-0.7
순 place150
Scored calls470 calls
Hit rate / Market-adjusted / Return-weighted45.0% / 46.7% / 48.9%
1-month return / Market / beta excess return / Peer excess-0.5% / -0.1% / -0.6
Bullish / Bearish / Neutral7.5% / 79.8% / 12.7%
Best horizon1d
Performance badgePersistent bias badge,Inverse badge
Main channelLifeWorthLiving
국적외
Note
Updated2026-10-28 07:00:00

Main stocks: #미국기술주 (266)#S&P500 (248)#나스닥 (100)#미국채금리 (72)#미국금융주 (48)

How scores are calculated

Jeremy Grantham's Shocking Market Prediction 2023 S&P 500 Crash & Top Stocks to Watch!

Investify · 2023-12-15 · 유튜브 시청 201 · Board Views 7 · International

International

유튜브 썸네일

원문 보기

다듬은 글 보기

welcome to inves toy where Finance meets foresight today we're diving deep into the world with a focus on one of the most renowned figures in the field Jeremy Grantham imagine a world where the stock market takes a nose dive sending shock waves through your Investments this isn't just a hypothetical scenario it's a prediction from a man who has eerily been right before stick around as we unveil the details of this chilling forecast and explore strategies to safeguard your portfolio Jeremy Grantham the co-founder of GMO and a maestro in Market predictions recently made headlines on Bloomberg's Marin talks money podcast known for his sharp Acumen Grantham has rung the alarm Bells with a dire warning a potential crash in the SP 500 but how severe could this be according to Grand we might see the SP plummet to about 3,000 points marking a near 30% decline from its current standings and if the conditions worsen brace yourselves for what he describes as a worst case scenario a staggering fall to 2,000 points a jaw-dropping 50% decline now why should we pay attention to grantham's predictions the answer lies in his track record he's not just any Market analyst he's the one who accurately called the do bust and the 2008 financial crisis his forecasts aren't mere speculation they're based on years of experience and deep Market understanding grantham's current view paints a picture of an overvalued Market heavily ryant on a group he refers to as The Magnificent 7 in these are primarily Tech Giants driving much of the SP 500's value but what happens when these overvalued stocks start to correct that's the Crux of grantham's concern ER turning our Focus to grantham's investment strategy let's delve into his moves in the third quarter of 2023 as revealed by 13 F filings these filings provide a window into the minds of major investors showing us where they're placing their bets in Q3 of 2023 Grantham made significant moves by increasing his stakes in three key Stocks by over 10% compared to the second quarter this decision indicates a strategic shift highlighting his confidence in these Investments amidst a turbulent Market forecast if you're finding this insight into grantham's strategies enlightening remember to hit that subscribe button we bring you the latest and most profound investment insights right here on inves ay as we navigate these predictions and strategies it's crucial to understand the implications for your Investments what do these moves mean for the average investor stay tuned as we analyze each of these key stocks in detail unraveling the potential behind grantham's choices let's take a closer look at the specifics of grantham's Investments starting with United Health Group Incorporated or un this Healthcare giant has seen a significant uptick in grantham's attention with a notable increase in stakes in the latter half of 2023 but why UNH the answer lies in its performance and financials from 2013 to 2023 UNH has shown a remarkable trajectory its Revenue surged from $122 billion in 2013 to an impressive $359 billion in 2023 that's a compound annual growth rate cagr of over 11% it's not just about the numbers it's about consistent growth in both revenue and net income a sign of a company that knows how to grow and sustain itself in terms of valuation UNH is trading at one point four times its sales and 24 times its net income these figures are crucial for investors as they help gauge the Stock's relative value a low price to sales ratio might suggest undervaluation making it an attractive Buy on the other hand the price to earnings ratio offers insight into how much investors are willing to pay for each dollar of earnings a vital indicator of Market sentiment next on grantham's list is Johnson and Johnson or J&J a household name J&J has been a long-term holding for Grantham stretching back to 2005 this longevity speaks volumes about the company's stability and grantham's confidence in it but what makes J&J a robust pick in grantham's portfolio Financial strength is a key factor J&J boasts a high return on Capital employed a metric that measures how effectively a company generates profits from its capital additionally the company projects a stable earnings per share growth of 4.3% annually from 2023 to 2027 this steady growth is a green flag for any investor looking for sustainable returns J&J also offers a dividend yield of 3.2% with a 47% EPS payout ratio Dividends are a critical aspect for many investors especially those seeking regular income from their Investments a yield of 3.2% is substantial especially in a low interest rate environment the valuation of J&J also merits attention as of November 2019 2023 its fair value per share stands at $182 while the current price hovers around1 152 this Gap indicates potential undervaluation suggesting room for growth and making it an attractive proposition for investors looking for Value buys now let's turn our Spotlight to another key player in grantham's portfolio Merk and Co Inc commonly known as MRK this pharmaceutical giant occupies a significant 1.96% of grantham's portfolio reflecting a deep-seated confidence in its potential but what's driving this confidence let's break it down over the Last 5 Years MRK has seen an impressive 43% increase in its stock value translating to an average annual growth of 7.4% this steady Ascent is a testament to mrk's resilience and strategic business model especially in a sector as volatile as Pharmaceuticals it's not just about short-term gains it's the consistency of growth that makes MRK a standout a crucial Factor contributing to mrk's appeal is its dividend growth in The Last 5 Years mrk's dividend per share has climbed from 48 cents to 73 this 88.7% annual growth in dividends is a significant indicator for investors especially those prior prioritizing income alongside capital appreciation it shows mrk's commitment to returning value to its shareholders an essential quality in a long-term investment the company's performance in the third quarter of 2023 further cements its status MRK reported a robust 7% year-over-year sales growth boyed by a staggering $6.3 billion revenue from one of its key drugs this impressive figure highlights mrk's ability to generate substan revenue streams a critical factor in sustaining growth and shareholder value from a valuation perspective MRK is currently trading at a forward price to earnings ratio of 12.1 times this is significant because it provides a glimpse into what the market is willing to pay today for a share of mrk's future earnings moreover MRK is expected to see an annual EPS growth rate of 14.4% over the next 5 years this projection is a strong indicator of the company's potential for continued financial success and its ability to outperform the broader Market as we wrap up our Deep dive into Jeremy grantham's Market insights and investment strategies let's revisit and consolidate the key takeaways grantham's warnings about a significant Market downturn carry weight especially given his track record of accurately predicting major economic shifts These Warnings are not just alarm Bells but a call to action for Savvy investors the focal point of grantham's current investment strategy is particularly noteworthy he's placing a strong emphasis on the health sector and undervalued stocks with substantial growth potential this approach highlights a strategic shift towards Industries and companies that not only offer stability in turbulent times but also promise long-term growth the health sector as exemplified by grantham's investments in UNH J&J and MRK stands out as a resilient and potentially lucrative field grantham's Diversified portfolio is a master class in mitigating risks while capitalizing on growth opportunities in a market teeming with uncertainties this diversification is a critical strategy for balancing potential risks and rewards it's about not putting all your eggs in one basket but rather spreading them across baskets that have the strongest weave investing much like any strategic Endeavor requires foresight adaptability and an acute understanding of the market dynamics as we've seen through grantham's approach being well-informed and strategically Diversified can make a significant difference in navigating the stock market's es and flows if you found this analysis helpful and are keen on staying ahead in the investment game don't forget to like this video And subscribe to inves Ay for more insightful content our journey doesn't end here it's just the beginning with each video we aim to empower you with knowledge and insight to make informed investment decisions thank you for watching inves ay where we bring the world of Finance to your doorstep keep an eye on those markets stay informed and most importantly stay invested until next time keep building your financial future with inves ay

← List으로
공유페이스북밴드

이 Articles에 대해 요청(숨김) 수정 요청

Comments 0